Positron emitting tracers in pre-clinical drug development

Area of Science:

• Molecular Imaging
• Radiochemistry
• Pharmacology

Background:

• Positron Emission Tomography (PET) is a sensitive molecular imaging technique.
• Developing targeted molecular probes enhances PET's utility in drug development.
• PET enables quantitative measurement of drug-target interactions.

Purpose of the Study:

• To review the application of positron emitting tracers in pre-clinical drug development.
• To highlight PET's role across various therapeutic areas.
• To underscore PET's value in optimizing drug discovery and evaluation.

Main Methods:

• Review of literature on positron emitting tracers in pre-clinical studies.
• Focus on applications in oncology, cardiology, neurosciences, and inflammatory diseases.
• Analysis of PET's role in target discovery and validation.

Main Results:

• PET tracers support the discovery of new drug targets.
• PET aids in clarifying disease pathophysiology.
• PET facilitates identification and validation of drug candidates.
• PET enables in vivo evaluation of pharmacokinetic and pharmacodynamic parameters.

Conclusions:

• PET imaging is a valuable tool throughout the drug development pipeline.
• Positron emitting tracers enhance efficiency and reduce costs in drug development.
• PET provides critical quantitative data for informed decision-making in pre-clinical research.